Home › Forums › Other Specialities › Therapeutics › DABIGATRAN- NEWER ANTICOAGULANT
- This topic has 0 replies, 1 voice, and was last updated 1 year, 1 month ago by
Anonymous.
-
AuthorPosts
-
-
December 21, 2023 at 1:45 pm #2822
Anonymous
InactiveDabigatran etexilate (Pradaxa, Boehringer Ingelheim; hereafter referred to as
dabigatran) is an orally administered anticoagulant that inhibits the thrombin
enzyme.Dabigatran has a UK marketing authorisation for the ‘prevention of
stroke and systemic embolismin adult patients with nonvalvular atrial
fibrillation with one or more of the following risk factors:previous stroke, transient ischaemic attack, or systemic embolism
left ventricular ejection fraction below 40%
symptomatic heart failure of New York Heart Association (NYHA) class 2 or above
age 75 years or overage 65 years or over with one of the following: diabetes mellitus, coronary artery
disease, or hypertension’.The summary of product characteristics states that the recommended daily
dose of dabigatran is 300 mg taken as one 150 mg capsule twice daily.
Therapy is continued long term.For patients aged 75–80 years, a dose of
220 mg taken as one 110 mg capsule twice daily can be considered at the
discretion of the physician for individual patients whose thromboembolic risk is
low and bleeding risk is high.Patients aged 80 years or older should be treated
with a daily dose of 220 mg taken as one 110 mg capsule twice daily because
of the increased risk of bleeding in this population.Dabigatran is contraindicated in people with severe renal impairment, active
clinically significant bleeding, organic lesions at risk of bleeding, impairment of
haemostasis, and hepatic impairment or liver disease expected to have an
impact on survival.Concomitant treatment with systemic ketoconazole,
cyclosporine, itraconazole or tacrolimus is also contraindicated.The most common adverse events in people receiving dabigatran are anaemia,
abdominal pain, diarrhoea, dyspepsia, gastrointestinal haemorrhage,
genitourinary haemorrhage (patients may notice blood in their urine), nausea
and nose bleeds.
For full details of adverse reactions and contraindications,
see the summary of product characteristics.National institute of Clinical Excellence- UK.
G Mohan.
-
-
AuthorPosts
- You must be logged in to reply to this topic.